SCHEMBL2927384

SCHEMBL2927384

COc1cc(/C=C/c2ccccc2)cc(OC)c1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 3/20 0.70
TUBB4A P04350 1/20 0.70
TUBB P07437 1/20 0.70
TUBA3C P0DPH7 1/20 0.70
TUBA1B P68363 1/20 0.70
TUBA4A P68366 1/20 0.70
TUBB4B P68371 1/20 0.70
TUBB3 Q13509 1/20 0.70
TUBB2A Q13885 1/20 0.70
TUBB8 Q3ZCM7 1/20 0.70
TUBA3E Q6PEY2 1/20 0.70
TUBA1A Q71U36 1/20 0.70
TUBA1C Q9BQE3 1/20 0.70
TUBB6 Q9BUF5 1/20 0.70
TUBB2B Q9BVA1 1/20 0.70
CYP1A2 P05177 2/20 0.65
CYP1A1 P04798 1/20 0.65
CYP1B1 Q16678 1/20 0.65
ABL1 P00519 1/20 0.65
BCR P11274 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927389 1.00 TUBB1 (0.70) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3645732 0.93 TUBB1 (0.70) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2718303 0.93 TUBB1 (0.70) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2718300 0.93 TUBB1 (0.70) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3645729 0.93 TUBB1 (0.70) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6844172 0.90 TUBB1 (0.76) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL14000544 0.90 TUBB1 (0.76) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL16372856 0.88 ABL1 (0.80) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL17843663 0.88 ABL1 (0.80) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL21428998 0.85 ERN1 (0.57) TUBB1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012129499-A1 TREATMENT OF INFLAMMATORY AND INFECTIOUS SKIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-09-27 WO claimed
CN-101225027-A Compound (E)-4-hydroxy-3,5-dimethoxystilbene and preparation thereof UNIV NORTHWEST NORMAL (CN) 2008-07-23 CN claimed
US-12595220-B2 Cocrystals of pterostilbene and compositions comprising them CENTER FOR INTELLIGENT RESEARCH IN CRYSTAL ENGINEERING, S.L. (ES) 2026-04-07 US disclosed
EP-4077258-B1 COCRYSTALS OF PTEROSTILBENE AND COMPOSITIONS COMPRISING THEM CENTER FOR INTELLIGENT RES IN CRYSTAL ENGINEERING S L (ES) 2026-03-25 EP disclosed
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis APICAL MOLECULAR BIOTECH CO., LTD. (TW) 2025-11-11 US disclosed
EP-4136063-B1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS APICAL MOLECULAR BIOTECH CO LTD (TW) 2025-10-22 EP disclosed
EP-4541351-A1 COMPOUNDS AND COMBINATION AS STIMULATORS OF COLLAGEN SYNTHESIS Center for Intelligent Research in Crystal Engineering, S.L. (ES) 2025-04-23 EP disclosed
CN-119193523-A Resveratrol methylase, expression vector, expression cassette and recombinant strain 中国科学院上海有机化学研究所 2024-12-27 CN disclosed
CN-114929659-B Co-crystals of pterostilbene and compositions containing same 晶体工程智能研究中心公司 2024-05-28 CN disclosed
US-11957727-B2 Prevention of neuroinflammation associated memory loss using nutraceutical compositions THERAPEUTIC SOLUTIONS INTERNATIONAL, INC (US) 2024-04-16 US disclosed
US-11951146-B2 Stimulation of NK cell activity by using a combination of broccoli, Nigella Sativa, Green Tea, and pterostilbene alone and together with metformin THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) 2024-04-09 US disclosed
EP-2231133-A2 METHOD AND COMPOSITIONS FOR ADMINISTERING RESVERATROL AND PTEROSTILBENE Rubin, David (US) 2010-09-29 EP disclosed
EP-2231847-A1 METHOD AND COMPOSITIONS FOR PRESERVING WINE Rubin, David (US) 2010-09-29 EP disclosed
CN-101820869-A Method for reducing oxidative stress and improving working memory by administering pterostilbene US AGRICULTURE 2010-09-01 CN disclosed
WO-2010046926-A2 NOVEL STILBENE ANALOGS APTUIT LAURUS PVT LTD (IN) 2010-04-29 WO disclosed
WO-2009089338-A2 METHOD AND COMPOSITIONS FOR ADMINISTERING RESVERATROL AND PTEROSTILBENE RUBIN DAVID (US) 2009-07-16 WO disclosed
WO-2009089334-A1 METHOD AND COMPOSITIONS FOR PRESERVING WINE RUBIN DAVID (US) 2009-07-16 WO disclosed
CN-101225027-A Compound (E)-4-hydroxy-3,5-dimethoxystilbene and preparation thereof UNIV NORTHWEST NORMAL (CN) 2008-07-23 CN disclosed
CN-101225027-A Compound (E)-4-hydroxy-3,5-dimethoxystilbene and preparation thereof UNIV NORTHWEST NORMAL (CN) 2008-07-23 CN disclosed
CN-101225027-A Compound (E)-4-hydroxy-3,5-dimethoxystilbene and preparation thereof UNIV NORTHWEST NORMAL (CN) 2008-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595220-B2 Cocrystals of pterostilbene and compositions comprising them SHBG, PSEN1, SREBF1 TUBB1 1066/4885TUBB4A 2352/4885TUBB 1356/4885
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis FABP1, GLS2, SLC1A5 TUBB1 4030/4885TUBB4A 4391/4885TUBB 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.